Epigenomic charting and functional annotation of risk loci in renal cell carcinoma
Amin H. Nassar(Brigham and Women's Hospital), Matthew L. Freedman(Brigham and Women's Hospital), Edward O’Connor(Dana-Farber Cancer Institute), Mark M. Pomerantz(Dana-Farber Cancer Institute), Ji-Heui Seo(Dana-Farber Cancer Institute), Heng Du(Brigham and Women's Hospital), Thomas Denize(Harvard University), Andrés Acosta(Indiana University Health), Michelle S. Hirsch(Perinatal Institute), Rosario I. Corona(University of California, Los Angeles), Gabrielle Bouchard(Dana-Farber Cancer Institute), Talal El Zarif(Yale University), Connor Bell(Dana-Farber Cancer Institute), Sayed Matar(Brigham and Women's Hospital), Gwo‐Shu Mary Lee(Dana-Farber Cancer Institute), Yue Hou(Inner Mongolia Medical University), Alexander Gusev(Dana-Farber Cancer Institute), John A. Steinharter(Memorial Sloan Kettering Cancer Center), Sabina Signoretti(Brigham and Women's Hospital), Marcos A. Fonseca(Cedars-Sinai Medical Center), Toni K. Choueiri(Harvard University), Pier Vitale Nuzzo(Dana-Farber Cancer Institute), Sylvan C. Baca(Broad Institute), Jacob E. Berchuck(Dana-Farber Cancer Institute), Elio Adib(Dana-Farber Brigham Cancer Center), Abdallah Flaifel(Brigham and Women's Hospital), Elizabeth P. Henske(Brigham and Women's Hospital), Viktória Tisza(Dana-Farber Cancer Institute), David A. Braun(Yale Cancer Center), Kate Lawrenson(Texas A&M University – San Antonio), Sachet A. Shukla(The University of Texas MD Anderson Cancer Center), Michel Alchoueiry(Brigham and Women's Hospital), David J. Kwiatkowski(Brigham and Women's Hospital), Sarah Abou Alaiwi(Yale New Haven Hospital), Monica He(Dana-Farber Cancer Institute), Sándor Spisák(HUN-REN Research Centre for Natural Sciences)
Cited by 35
Related Papers
The Immune Landscape of Cancer
|Immunity|2018|6.2k
The Somatic Genomic Landscape of Glioblastoma
|Cell|2013|5.2k
Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity
|Cell|2015|4.2k
The landscape of somatic copy-number alteration across human cancers
|Nature|2010|4.1k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k